Sustained Neurological Recovery After Stroke in Aged Rats Treated With a Novel Prostacyclin Analog.

ABSTRACT:

Background and purpose

Targeting the prostaglandin I₂ prostanoid (IP) receptor to reduce stroke injury has been hindered by the lack of selective drugs. MRE-269 is the active metabolite of selexipag showing a high selectivity toward the IP receptor. Selexipag has been recently approved for clinical use in pulmonary hypertension. We hypothesized that postischemic treatment with MRE-269 provides long-lasting neuroprotection with improved neurological outcomes in a clinically relevant rat stroke model.

Methods

Aged male Sprague-Dawley rats underwent transient middle cerebral artery occlusion and were randomly selected to receive either vehicle or MRE-269 (0.25 mg/kg) intravenously starting at 4.5 hours post ischemia. Accelerating rotarod and adhesive removal tests we

SUBMITTER: Yang C 

PROVIDER: S-EPMC5508605 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature